Axial Spondyloarthritis
📧 Sign up to get email alerts when something new happens for Axial Spondyloarthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-05Clinical Trial Update: to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis [Phase 2]
Phase 2 trial evaluating preliminary efficacy and safety of GR1501 Injection for active axial spondyloarthritis has completed.
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis [Phase 3]
Phase 3 trial results evaluate the efficacy and safety of Upadacitinib in adults with axial spondyloarthritis. The results were completed an…
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients [Phase 3]
Phase 3 clinical trial updating on hip denervation and intra-articular hydration for axial spondyloarthritis with hip damage; study complete…
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis [Phase 2]
Phase 2 trial assessing efficacy and safety of namilumab for moderate-to-severe axial spondyloarthritis completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) [Phase 4]
A Phase 4 clinical trial evaluating a reduced dose of a TNF inhibitor in patients with ankylosing spondylitis and axial spondyloarthritis; s…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis [Phase 3]
Phase 3 long-term extension study of ixekizumab in axial spondyloarthritis completed with results posted.
-
FDA approval · 2021-05-28FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for COSENTYX (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site [Phase 3]
Phase 3 trial evaluating the efficacy and safety of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis including a…
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU [Phase 4]
Phase 4 trial evaluating certolizumab pegol for reducing anterior uveitis flares in patients with axial spondyloarthritis and a history of A…
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis [Phase 4]
A Phase 4 clinical trial evaluating non-steroidal anti-inflammatory drugs in axial spondyloarthritis was terminated with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS [Phase 3]
Phase 3 trial comparing certolizumab pegol to placebo in nonradiographic axial spondyloarthritis completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis
Clinical trial update on MRI and biomarkers in golimumab-treated patients with axial spondyloarthritis; study completed with results posted.
-
FDA approval · 2020-05-29FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under…
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo [Phase 3]
A Phase 3 study assessing maintenance of sustained remission with CZP versus placebo in axial spondyloarthritis and ankylosing spondylitis h…
-
CLINICAL_TRIALS trial_result · 2020-04-07Clinical Trial Update: Ultrasound Guided Epidural Block in Axial SPA [Phase 4]
Phase 4 trial update on ultrasound-guided epidural block for axial spondyloarthritis has completed.
-
FDA approval · 2020-03-26FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TALTZ (ixekizumab) from Eli Lilly and Company, indicating an updated or expanded indication …
-
CLINICAL_TRIALS trial_result · 2020-03-13Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial update for ixekizumab in nonradiographic axial spondyloarthritis has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein [Phase 4]
Phase 4 clinical trial update on a recombinant TNF-α receptor fusion protein for axial spondyloarthritis shows completed status.
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)
A post-marketing observational study investigating the effectiveness of combining adalimumab with active supervised training in axial spondy…
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis [Phase 3]
A Phase 3 study evaluating the biodistribution and detection of radiolabeled anti-TNFα in patients with active rheumatoid arthritis and acti…
-
FDA approval · 2019-07-23FDA Approved: HADLIMA — Original Application (Organon LLC)
FDA approves Hadlima (adalimumab-bwwd) from Organon as a biosimilar to Humira under the original application BLA761059. It is indicated for …
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment [Phase 4]
Phase 4 trial investigating an intense treatment approach versus routine treatment for early axial spondyloarthritis; study terminated with …
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
Clinical trial update assessing the efficacy of etanercept over 12 months in routine treatment of rheumatoid arthritis and related inflammat…
-
CLINICAL_TRIALS trial_result · 2019-06-21Clinical Trial Update: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta [Phase 1]
Phase 1 postmarketing transfer study evaluating Cimzia (certolizumab pegol) from mother to infant via placenta has completed with results po…